Guillaume Dutheuil, Killian Oukoloff, Julien Korac, François Lenoir, Mohamed El Bousmaqui, Nicolas Probst, Alexey Lapin, Galina Nakhabina, Catherine Sorlet, Nicolas Parmentier, Delphine Karila, Nugzar Ghavtadze, Paméla Casault, Stephen Claridge, Selma Sapmaz, Martin J Slater, Graeme L Fraser
{"title":"Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models.","authors":"Guillaume Dutheuil, Killian Oukoloff, Julien Korac, François Lenoir, Mohamed El Bousmaqui, Nicolas Probst, Alexey Lapin, Galina Nakhabina, Catherine Sorlet, Nicolas Parmentier, Delphine Karila, Nugzar Ghavtadze, Paméla Casault, Stephen Claridge, Selma Sapmaz, Martin J Slater, Graeme L Fraser","doi":"10.1021/acs.jmedchem.4c02225","DOIUrl":null,"url":null,"abstract":"<p><p>METTL3 is the RNA methyltransferase predominantly responsible for the addition of N<sup>6</sup>-methyladenosine (m<sup>6</sup>A), the most abundant modification to mRNA. The prevalence of m<sup>6</sup>A and the activity and expression of METTL3 have been linked to the appearance and progression of acute myeloid leukemia (AML), thereby making METTL3 an attractive target for cancer therapeutics. We report herein the discovery and optimization of small-molecule inhibitors of METTL3, culminating in the selection of <b>EP652</b> as an <i>in vivo</i> proof-of-concept compound. <b>EP652</b> potently inhibits the enzymatic activity of METTL3, has favorable PK parameters, and demonstrates efficacy in preclinical oncology models, indicating that pharmacological inhibition of METTL3 is a viable strategy for the treatment of liquid and solid tumors.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":" ","pages":"2981-3003"},"PeriodicalIF":6.8000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02225","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
METTL3 is the RNA methyltransferase predominantly responsible for the addition of N6-methyladenosine (m6A), the most abundant modification to mRNA. The prevalence of m6A and the activity and expression of METTL3 have been linked to the appearance and progression of acute myeloid leukemia (AML), thereby making METTL3 an attractive target for cancer therapeutics. We report herein the discovery and optimization of small-molecule inhibitors of METTL3, culminating in the selection of EP652 as an in vivo proof-of-concept compound. EP652 potently inhibits the enzymatic activity of METTL3, has favorable PK parameters, and demonstrates efficacy in preclinical oncology models, indicating that pharmacological inhibition of METTL3 is a viable strategy for the treatment of liquid and solid tumors.
期刊介绍：
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
